DGX Stock Overview
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Quest Diagnostics Incorporated Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$137.38 |
| 52 Week High | US$145.58 |
| 52 Week Low | US$119.59 |
| Beta | 0.89 |
| 1 Month Change | 3.77% |
| 3 Month Change | 9.90% |
| 1 Year Change | 0.64% |
| 3 Year Change | -1.13% |
| 5 Year Change | 38.53% |
| Change since IPO | 3,825.14% |
Recent News & Updates
Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26
We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Recent updates
Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Feb 06Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 11Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price
Dec 24Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Is There Now An Opportunity In Quest Diagnostics Incorporated (NYSE:DGX)?
Dec 06Quest Diagnostics' (NYSE:DGX) Returns Have Hit A Wall
Nov 18Quest Diagnostics: Moving Past Covid
Oct 25Here's Why Quest Diagnostics (NYSE:DGX) Can Manage Its Debt Responsibly
Sep 25What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Sep 04Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
Aug 13Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jul 11Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Jun 09Quest Diagnostics: Healthier Diagnosis
May 30Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?
May 24Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
May 09An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued
Mar 22What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Feb 19Why Quest Diagnostics Isn't A 'Buy', My Oh My
Feb 14Quest Diagnostics' (NYSE:DGX) Upcoming Dividend Will Be Larger Than Last Year's
Feb 05Quest Diagnostics Q4 2022 Earnings Preview
Feb 01Quest Diagnostics' unit Pack Health to expand Alabama facility
Jan 17Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 17Returns On Capital Are Showing Encouraging Signs At Quest Diagnostics (NYSE:DGX)
Jan 03An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 46% Undervalued
Dec 04Quest Diagnostics declares $0.66 dividend
Nov 14Is Now The Time To Look At Buying Quest Diagnostics Incorporated (NYSE:DGX)?
Nov 06Decode Health, Quest to collaborate to improve biomarker discovery for drug discovery
Oct 18Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Oct 06Quest Diagnostics to acquire select assets of Summa Health
Oct 05Quest Diagnostics: The Market Is Overlooking Long-Term Prospects
Sep 15Quest Diagnostics: Valuation Looks Good As Covid Testing Demand Tapers
Sep 09Returns Are Gaining Momentum At Quest Diagnostics (NYSE:DGX)
Aug 22Shareholder Returns
| DGX | US Healthcare | US Market | |
|---|---|---|---|
| 7D | 2.3% | -2.3% | 0.7% |
| 1Y | 0.6% | -0.01% | 23.9% |
Return vs Industry: DGX underperformed the US Healthcare industry which returned 2.1% over the past year.
Return vs Market: DGX underperformed the US Market which returned 24.2% over the past year.
Price Volatility
| DGX volatility | |
|---|---|
| DGX Average Weekly Movement | 3.1% |
| Healthcare Industry Average Movement | 7.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: DGX has not had significant price volatility in the past 3 months.
Volatility Over Time: DGX's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1967 | 44,000 | Jim Davis | www.questdiagnostics.com |
Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals.
Quest Diagnostics Incorporated Fundamentals Summary
| DGX fundamental statistics | |
|---|---|
| Market cap | US$15.15b |
| Earnings (TTM) | US$842.00m |
| Revenue (TTM) | US$9.29b |
18.1x
P/E Ratio1.6x
P/S RatioIs DGX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DGX income statement (TTM) | |
|---|---|
| Revenue | US$9.29b |
| Cost of Revenue | US$6.22b |
| Gross Profit | US$3.07b |
| Other Expenses | US$2.23b |
| Earnings | US$842.00m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 7.58 |
| Gross Margin | 33.08% |
| Net Profit Margin | 9.07% |
| Debt/Equity Ratio | 72.0% |
How did DGX perform over the long term?
See historical performance and comparison